Intensive pharmacologic treatment in patients with acute non ST-segment elevation myocardial infarction who did not undergo percutaneous coronary intervention

Circulation Journal

Volumn 72, Issue 9, 2008, Pages 1403-1409

  Hae, Chang Jeong ^a   Young, Keun Ahn ^a   Myung, Ho Jeong ^a   Shung, Chull Chae ^a   Jong, Hyun Kim ^a   In, Whan Seong ^a   Young, Jo Kim ^a   Seung, Ho Hur ^a   Dong, Hoon Choi ^a   Taek, Jong Hong ^a   Jung, Han Yoon ^a   Jae, Young Rhew ^a   Jei, Keon Chae ^a   Doo, Il Kim ^a   In, Ho Chae ^a   Bon, Kwon Koo ^a   Byung, Ok Kim ^a   Nae, Hee Lee ^a   Jin, Yong Hwang ^a   Seok, Kyu Oh ^a   Myeong, Chan Cho ^a   Kee, Sik Kim ^a   Kyoung, Tae Jeong ^a   Myoung, Yong Lee ^a   Chong, Jin Kim ^a   Wook, Sung Chung ^a   Seung, Jea Tahk ^b   Jang, Ho Bae ^b   Seung, Woon Rha ^b   Keum, Soo Park ^b   Kyoo, Rok Han ^b   Tae, Hoon Ahn ^b   Moo, Hyun Kim ^b   Ki, Bae Seung ^b   Ju, Young Yang ^b   Chong, Yun Rhim ^b   Hyeon, Cheol Gwon ^b   Seong, Wook Park ^b   Young, Youp Koh ^b   Seung, Jae Joo ^b   Soo, Joong Kim ^b   Dong, Kyu Jin ^b   Jin, Man Cho ^b   Yang, Soo Jang ^b   Jeong, Gwan Cho ^b   Seung, Jung Park ^b   more..

^a Chonnam National University Medical School   (South Korea)

^b NONE

Author keywords

Drugs; Myocardial infarction; Non ST segment elevation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NICORANDIL; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HOSPITAL MORTALITY; HUMANS; KOREA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 50549100902     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0048     Document Type: Article

References (39)

1. Jason WR, Eric DP, Anita YC, Matthew TR, Magnus O, Christopher PC, et al. Optimal timing of intervention in non-ST-Segment elevation acute coronary syndromes insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation 2005; 112: 3049-3057.
2. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
3. Ohman EM, Roe MT, Smith SC Jr, Brindis RG, Christenson RH, Harrington RA, et al. Care of non-ST-segment elevation patients: Insights from the CRUSADE national quality improvement initiative. Am Heart J 2004; 148: 34-39.
4. Gulati M, Patel S, Jaffe AS, Joseph AJ, Calvin JE Jr. Impact of contemporary guideline compliance on risk stratification models for acute coronary syndromes in The Registry of Acute Coronary Syndromes. Am J Cardiol 2004; 94: 873-878.
5. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: Diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129: 1349-1366.
6. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: A prospective study. Intensive Care Med 2000; 26: 31-37.
7. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842.
8. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
11. Popma JJ, Suk J. Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001; 88: 25-29.
12. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2003; 24: 1174-1175.
13. Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353: 2714-2718.
14. Alexander H, Fons W, Jan GP, Freek WA, Jan HC, Robbert J. The Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) investigators. Lancet 2007; 369: 827-835.
15. Dziewierz A, Siudak Z, Rakowski T, Mielecki W, Giszterowicz D, Dubiel JS, et al. More aggressive pharmacological treatment may improve clinical outcome in patients with non-ST-elevation acute coronary syndromes treated conservatively. Coron Artery Dis 2007; 18: 299-303.
16. Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, et al. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circ J 2005; 69: 159-164.
17. Valencia R, Price MJ, Sawhney N, Lee SS, Wong GB, Gollapudi RR, et al. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE Trial). Am J Cardiol 2007; 100: 1099-1102.
18. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Valgimigli M, Abbate A, Sangiorgi G, et al. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. Am Heart J 2007; 153: 587-593.
19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
20. Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al. Japan Assessment of Pitavastatin and AtorvastatiN in Acute Coronary Syndrome (JAPAN-ACS): Rationale and design. Circ J 2006; 70: 1624-1628.
21. Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sautiere K, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol 2006; 98: 1144-1149.
22. Dagenais GR, Pogue J, Fos K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet 2006; 368: 581-588.
23. Kojima S, Matsui K, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, et al. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J 2007; 71: 301-307.
24. Iijima R, Nakajima R, Sugi K, Nakamura M. Improvement of postprandial hyperglycemia has a positive impact on epicardial flow of entire coronary tree in acute coronary syndromes patients. Circ J 2007; 71: 1079-1085.
25. Lee SH, Choi SH, Choi S, Jung JH, Lee N, Choi YJ, et al. Impact of chronotropic effect of cilostazol after acute myocardial infarction: Insights from change in left ventricular volume and function. Circ J 2007; 71: 106-111.
26. Kim JH, Jeong MH, Yun KH, Kim KH, Kang DK, Hong SN, et al. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J 2005; 69: 306-310.
27. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol 2007; 99: 879-884.
28. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70: 1379-1384.
29. Hong SN, Ahn Y, Yoon NS, Lee KH, Kim YS, Hwang SH, et al. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. Am J Cardiol 2007; 99: 1051-1054.
30. Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006; 70: 1372-1378.
31. Kim W, Jeong MH, Kim KH, Park JC, Lee SH, Rhew JY, et al. The rescue use of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; Reo-Pro®) in high-risk patients with acute myocardial infarction underwent percutaneous coronary intervention. Korean Circ J 2001; 31: 492-499.
32. Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-1924.
33. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e148-e304.
34. Valencia R, Price MJ, Sawhney N, Lee SS, Wong GB, Gollapudi RR, et al. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE Trial). Am J Cardiol 2007; 100: 1099-1102.
35. Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 2007; 116: 305-315.
36. Bentura HO. Benefits of inpatient initiation of beta-blockers. Am Heart J 2004; 148: 944-950.
37. Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295: 1912-1920.
38. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65 years of age. Am J Cardiol 2007; 100: 1061-1067.
39. Hong YJ, Jeong MH, Lim SY, Lee SR, Hong SN, Kim KH, et al. The long-term clinical outcomes of combination therapy with angiotensin II type I receptor blocker and simvastatin after percutaneous coronary intervention. Korean Circ J 2005; 35: 877-882.